Production (Stage)
Pasithea Therapeutics Corp.
KTTA
$0.69
$0.00070.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.69% | -10.50% | -18.75% | -14.31% | -19.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.37% | -10.82% | 8.51% | 13.28% | 22.48% |
| Operating Income | 17.37% | 10.82% | -8.51% | -13.28% | -22.48% |
| Income Before Tax | 15.50% | 10.34% | -8.45% | -8.36% | -17.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.50% | 10.34% | -8.45% | -8.36% | -17.54% |
| Earnings from Discontinued Operations | -- | -- | 98.87% | 99.11% | 91.73% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.44% | 12.89% | 1.60% | 3.63% | -2.42% |
| EBIT | 17.37% | 10.82% | -8.51% | -13.28% | -22.48% |
| EBITDA | 18.06% | 11.28% | -7.70% | -11.51% | -19.43% |
| EPS Basic | 23.42% | 1.52% | -20.74% | -15.26% | -14.29% |
| Normalized Basic EPS | 22.55% | -1.33% | -42.98% | -39.13% | -42.01% |
| EPS Diluted | 23.42% | 1.52% | -20.74% | -15.26% | -14.29% |
| Normalized Diluted EPS | 22.55% | -1.33% | -42.98% | -39.13% | -42.01% |
| Average Basic Shares Outstanding | 14.88% | -13.95% | -15.09% | -12.10% | -4.58% |
| Average Diluted Shares Outstanding | 14.88% | -13.95% | -15.09% | -12.10% | -4.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |